A more active approach to T2DM treatment has recently been involved in the disruption of dietary monosaccharide absorption by inhibiting α-glucosidase [55] and PTP1B, which is involved in the dephosphorylation and inactivation of insulin receptors and attenuates insulin signaling [56]. Here, PTPN1 is linked to type 2 diabetes mellitus.